ロード中...
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression
BACKGROUND: A rapid and early monoclonal (M) protein response during initial therapy in patients with multiple myeloma has been identified as a predictor of superior long-term outcome in some, but not all studies. METHODS: To determine if the parameter of M protein reduction was of value in the rela...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4149315/ https://ncbi.nlm.nih.gov/pubmed/21328327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25937 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|